Joint (JYNT) AI Stock Analysis

• Market Cap: $145.39M
• Dividend Yield: N/A
• Average Volume (3M): 133.85K
• Price to Earnings (P/E): 77.3
• Beta (1Y): 0.99
• Revenue Growth: -54.93%
• EPS Growth: N/A
• Country: US
• Employees: 443
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.02
• Shares Outstanding: 14,866,192
• 10 Day Avg. Volume: 93,155
• 30 Day Avg. Volume: 133,848
• PEG Ratio: 2.01
• Price to Book (P/B): 7.68
• Price to Sales (P/S): 3.04
• P/FCF Ratio: 19.27
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 83.05
• Enterprise Value/Gross Profit: -11.86
• Enterprise Value/Ebitda: -83.68
• 1Y Price Target: $11.33
• Price Target Upside: 15.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $10.00 ▲(2.25% Upside)

The score is primarily weighed down by weak and unstable recent fundamentals, including an extreme TTM revenue decline and losses, partially offset by low leverage and still-positive cash generation. Technicals are modestly improving short-term but remain weak longer-term, while valuation is demanding with a high P/E. The latest earnings call adds some support via improving EBITDA, strong cash, and buybacks, but guidance and sales trends remain mixed.

Positive Factors

Low leverage / strong balance sheet

Very low leverage gives the company durable financial flexibility to fund refranchising, absorb cyclical weakness, and pursue buybacks or opportunistic investments without immediate refinancing pressure. This reduces default and liquidity risk over the next several quarters.

Solid cash position and buyback capacity

A near-term cash cushion of ~$29.7M supports operations, strategic refranchising, and an authorized buyback program. That cash provides a durable buffer while management executes digital initiatives and reduces corporate clinic exposure, improving optionality over 2–6 months.

Progress on refranchising and asset-light shift

Active refranchising and clinic sales shift the model toward asset-light franchising, lowering capital intensity and operating overhead. If sustained, this structural shift can improve margins, cash conversion, and scalability over the medium term.

Negative Factors

Extreme TTM revenue collapse

An extreme 92.1% TTM revenue decline is a durable red flag for demand, reporting scope, or divestiture impacts. Such a collapse undermines operational scale, pricing leverage and long-term margin sustainability, raising execution risk for recovery plans.

Persistent losses and weak returns

Ongoing net losses and multi-year negative ROE indicate the company is not converting assets into consistent shareholder returns. This constrains reinvestment, makes sustained buybacks and growth funding difficult, and highlights underlying profitability issues.

Declining system-wide sales and new patient trends

Falling system-wide sales, negative comps, and softer new patient acquisition point to weakening core demand and competitive or macro pressure. These trends threaten revenue recovery, limit franchise economics improvements, and pressure cash flow over the next several quarters.

Joint Business Overview & Revenue Model

Company Description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

How the Company Makes Money

Joint generates revenue through the sale of its dietary supplements and joint health products, which are distributed via various channels including e-commerce platforms, retail partnerships, and direct-to-consumer sales. The company has established key partnerships with health and wellness retailers, enabling broader market access and visibility for its products. Additionally, Joint may engage in subscription models for ongoing customer purchases, providing a steady revenue stream. The company's marketing strategies, including influencer partnerships and targeted advertising, contribute to customer acquisition and brand loyalty, further enhancing its earnings potential.

Joint Financial Statement Overview

Summary

Financials are pressured by a sharp TTM revenue collapse (-92.1%) and ongoing net losses (TTM net margin -2.6%) despite historically stronger periods. Offsetting this, leverage is low (TTM debt-to-equity 0.09) and operating/free cash flow are positive, though free cash flow declined meaningfully (TTM -51.7%) and remains volatile.

Income Statement

The income statement shows a sharp deterioration in scale and profitability. Revenue trends were solid historically (2020–2024 annual growth was positive), but TTM (Trailing-Twelve-Months) shows an extreme revenue collapse (down 92.1%), which overwhelms prior momentum. Profitability is also weak: the company is currently loss-making (TTM net margin -2.6%), and annual results have been negative in 2023 and 2024 after strong profitability in 2020–2021. While gross margin has historically been high, earnings consistency has broken down and the recent revenue trajectory is the key risk.

Balance Sheet

The balance sheet is a relative strength, with low leverage in the most recent periods. Debt levels are modest versus equity (debt-to-equity of 0.04 in 2024 and 0.09 in TTM), suggesting financial flexibility and lower refinancing risk. The main weakness is returns: profitability has been insufficient to generate attractive shareholder returns (negative return on equity in 2023, 2024, and TTM), indicating the balance sheet strength is not translating into consistent earnings power.

Cash Flow

Cash generation is mixed but better than earnings. Operating cash flow remains positive across the periods provided, including TTM, and free cash flow is also positive in TTM—supportive for liquidity. However, cash flow momentum has weakened: TTM free cash flow declined 51.7%, and both operating and free cash flow have been volatile year-to-year. A further watch item is that cash flow has not consistently kept pace with the company’s needs and variability in profits, highlighting execution risk during the current downturn.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44M	52.16M	46.98M	101.25M	80.01M	58.68M
Gross Profit	-10.11M	40.65M	36.50M	92.08M	72.35M	52.18M
EBITDA	-1.43M	2.90M	8.88M	7.89M	10.07M	8.18M
Net Income	-799.12K	-5.80M	-9.75M	626.71K	7.57M	13.17M
Balance Sheet
Total Assets	69.39M	83.15M	87.21M	93.49M	87.06M	65.88M
Cash, Cash Equivalents and Short-Term Investments	30.71M	25.05M	18.15M	9.75M	19.53M	20.55M
Total Debt	2.09M	795.03K	2.86M	26.06M	23.62M	18.48M
Total Liabilities	46.66M	62.48M	62.44M	60.90M	56.75M	44.75M
Stockholders Equity	22.70M	20.65M	24.75M	32.56M	30.28M	21.13M
Cash Flow
Free Cash Flow	1.63M	8.23M	9.68M	2.31M	6.85M	8.03M
Operating Cash Flow	3.07M	9.42M	14.68M	8.21M	13.84M	11.18M
Investing Cash Flow	6.52M	-631.55K	-6.19M	-17.90M	-12.75M	-4.60M
Financing Cash Flow	-873.09K	-2.00M	174.12K	328.61K	-2.00M	5.60M

Joint Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JYNT, the sentiment is Positive. The current price of 9.78 is above the 20-day moving average (MA) of 9.63, above the 50-day MA of 9.04, and below the 200-day MA of 9.92, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 55.31 is Neutral, neither overbought nor oversold. The STOCH value of 22.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JYNT.

Joint Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	74 Outperform	$2.22B	22.08	9.94%	1.80%	23.74%	-18.99%
USPH	63 Neutral	$1.28B	35.28	7.30%	2.25%	17.50%	154.28%
ASTH	62 Neutral	$1.14B	119.68	1.29%	―	68.17%	-85.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JYNT	49 Neutral	$145.39M	77.31	-1.37%	―	-54.93%	―
TOI	46 Neutral	$266.61M	-4.21	-3407.86%	―	21.67%	16.74%

Joint Corporate Events

Joint Reaches Governance Agreement With Bandera Partners

On January 5, 2026, Joint entered into a letter agreement with Bandera Partners LLC and Jefferson Gramm that provides for Mr. Gramm to be included in the company’s slate of director nominees at its 2026 annual meeting of stockholders and for the board to recommend that shareholders vote in favor of his election. The agreement, which imposes voting commitments, standstill obligations, and transfer restrictions on Bandera’s holdings of Joint’s common stock, is set to remain in effect until the earlier of thirty days before the director-nomination deadline for the 2027 annual meeting or January 21, 2027, signaling a negotiated governance arrangement with an important shareholder through that period.

The most recent analyst rating on (JYNT) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Corp. Terminates Southern California Clinics Sale

On December 5, 2025, The Joint Corp. entered into an Asset Purchase Agreement to sell 22 company-owned or managed clinics in Virginia, North Carolina, and South Carolina to a group of buyers for approximately $1.5 million. The transaction, which involves existing franchise community members, is expected to enhance the company’s strategic initiatives and growth. Additionally, on December 11, 2025, The Joint Corp. terminated a previous agreement to sell 45 clinics in Southern California due to the buyer’s failure to meet closing conditions, with no penalties incurred.

The most recent analyst rating on (JYNT) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Corp. Sells Clinics in $4.5M Deal

On November 2, 2025, The Joint Corp. entered into an Asset Purchase Agreement with Elite Chiro Group to sell the assets of 45 clinics in Southern California for $4.5 million. This transaction includes franchise rights and is subject to certain conditions, including lease assignments and customary closing conditions. Additionally, The Joint Corp. has been authorized to repurchase an additional $12 million of its stock, reflecting confidence in its growth and profitability strategies. The company reported a 6% revenue increase in Q3 2025 compared to Q3 2024, with significant improvements in net income and adjusted EBITDA, despite a slight decline in system-wide sales.

The most recent analyst rating on (JYNT) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.